Articles tagged "Adverse effects"

2022 American Transplant Congress
Evaluation of Conversion from Immediate Release (IR) Tacrolimus to LCP-Tacrolimus (Envarsus XR®, LCP) in Heart Transplant Recipients
E. Foster¹, A. Iaria¹, J. Negrelli², M. Fine², M. Yu², M. Liebo²
¹University of Illinois at Chicago, Chicago, IL, ²Loyola University Medical Center, Maywood, IL
*Purpose: The purpose of this study was to assess outcomes in heart transplant recipients who were converted from IR tacrolimus to LCPT. Limited data exists…
2022 American Transplant Congress
Outcome Predictors with Perioperative Kidney Transplant Midodrine Usage
R. Watson¹, S. Mullins², S. Williams³, F. Fakhre⁴, K. Robichaux⁴, S. Mohammed⁴, M. Gosselin³, A. Kumar⁵, J. Buggs¹, V. Bowers¹
¹Transplant Surgery, Tampa General Hospital, Tampa, FL, ²Florida A &M University, Tallahassee, FL, ³University of Tampa, Tampa, FL, ⁴University of South Florida, Tampa, FL, ⁵Morsani College of Medicine, University of South Florida, Tampa, FL
*Purpose: Midodrine is an alpha-1 agonist drug commonly used to aid hypotension in kidney transplant patients. Little is described regarding outcomes with midodrine in kidney…
2022 American Transplant Congress
Longitudinal Analysis of the Gut Microbiota Structure and Function After Renal Transplantation
A. Vaitkute¹, F. Yuen Chang¹, A. Greco², S. Chong¹, H. Mahdi³, M. Bajaj-Elliott², A. Pesenacker¹, R. Motallebzadeh¹
¹Institute of Immunity and Transplantation, UCL, London, United Kingdom, ²Institute of Child Health, UCL, London, United Kingdom, ³Department of Renal Medicine, UCL, London, United Kingdom
*Purpose: Despite marked improvements in outcomes after renal transplantation, graft loss from alloimmune pathology and adverse side effects including urinary tract infections and diarrhoea remain…
2022 American Transplant Congress
Development of a Patient-Reported Outcome Measure of Neurological Side Effects from Immunosuppression in Kidney Transplant Recipients
C. Hurt¹, G. J. Greene¹, J. Friedewald², D. P. Ladner², A. Waterman³, D. Cella¹, D. Peipert¹
¹Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Department of Surgery and J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX
*Purpose: Though kidney transplant is the optimal treatment for most individuals with end stage kidney disease, recipients experience significant side effects associated with their required…
2022 American Transplant Congress
Impact of Dysgeusia on Transplant Recipients with Refractory Cytomegalovirus with/without Resistance Receiving Maribavir: Post-Hoc Analyses from a Phase 3 Randomized Trial
F. Silveira¹, S. Haider², D. Kaul³, O. Witzke⁴, J. Gu⁵, A. Sundberg⁵
¹Univ. Pittsburgh, Pittsburgh, PA, ²McMaster Univ., Hamilton, ON, Canada, ³Univ. Michigan, Ann Arbor, MI, ⁴Univ. Duisburg-Essen, Essen, Germany, ⁵Takeda Development Center Americas, Inc., Lexington, MA
*Purpose: In a Phase 3 study (SOLSTICE; NCT02931539), maribavir (MBV) was superior to investigator-assigned therapies (IAT; val/ganciclovir, foscarnet, or cidofovir) for CMV clearance at Wk…
2022 American Transplant Congress
The Impact of Long-Term Exposure to Tacrolimus on Chronic Kidney Disease Following Lung Transplantation: A Retrospective Analysis from a Single Transplantation Center
D. Xiong, J. Zhang, J. Chen
Lung Transplantation Center, Department of Thoracic Surgery, Wuxi People’s Hospital Affiliated to Nanjing Medical Univer, Wuxi, China
*Purpose: Chronic kidney disease (CKD) is a progressive and irreversible complication in lung transplant patients who have received long-term treatment with tacrolimus. This study aimed…
2022 American Transplant Congress
The Sustained Impact of a Minimization Protocol on Peri-Operative Opioid Use in Kidney Transplantation
N. Patel, T. Carcella, J. Marable, V. Rohan, S. Bethi, P. Baliga, D. Dubay, J. N. Fleming, D. Taber
-MUSC, -Charleston, SC
*Purpose: Opioid use following kidney transplant (KTX) is associated with higher graft and patient loss. Thus, in 2019 we implemented an opioid minimization quality improvement…
2022 American Transplant Congress
Conversion of Tacrolimus Immediate Release to LCP Tacrolimus in Obese Kidney Transplant Recipients
J. Newman, N. Patel, S. Patel, T. Sprague, E. Andrade, N. Rao, F. Bartlett, D. DuBay, V. Rohan, M. Casey, D. Taber
MUSC, Charleston, SC
*Purpose: Data describing the safety, efficacy and conversion ratio of tacrolimus immediate release (IR) to LCP-tacrolimus (LCP) in obese patients (BMI > 30) is lacking.…
2022 American Transplant Congress
Prevalence of Mycophenolate Mofetil (MMF) Discontinuation and Outcomes in Pediatric Kidney Transplants (PKTX): A PNRC Study
A. Moudgil¹, K. Sgambat¹, E. Benoit², A. Jain³, M. Seifert⁴, C. Katsoufis⁵, L. Harshman⁶, A. Mansuri⁷, M. Somers⁸
¹Nephrology, Children's National Med. Ctr., Washington, DC, ²Nephrology, Boston's Children's Hospital, Boston, MA, ³Nephrology, Wayne State University, Troy, DC, ⁴Nephrology, The University of Alabama, Birmingham, AL, ⁵Nephrology, Holtz Children's Hospital, Miami, FL, ⁶Nephrology, University of Iowa, Iowa City, IA, ⁷Nephrology, Children's Hospital of Georgia, Augusta, GA, ⁸Nephrology, Boston Children's Hospital, Boston, MA
*Purpose: MMF is discontinued in PKTX for various reasons. In this Pediatric Nephrology Research Consortium (PNRC) study, we determined prevalence and reasons for MMF discontinuation…
2022 American Transplant Congress
Safety and Mortality Benefit of Direct Oral Anticoagulants in Kidney Transplant
C. Firth, M. Apolinario, F. Shamoun, E. Lim, N. Zhang, M. Keddis
Mayo Clinic, Scottsdale, AZ
*Purpose: Direct oral anticoagulants (DOACs) are increasingly used in renal transplant recipients (RTR). We aim to identify bleeding events and all-cause mortality between DOACs and…